Spectral Medical Inc is primarily active in the healthcare industry.

The main competitors of Spectral Medical Inc in the market include companies such as Baxter International Inc, Fresenius Medical Care AG & Co KGaA, and Becton, Dickinson and Company.

Spectral Medical Inc is a leading biotechnology company specializing in the development and commercialization of innovative solutions for patient care. Founded in 1991, the company has a rich history of advancing critical care and medical technology. With a focus on improving outcomes for patients experiencing septic shock, Spectral Medical Inc has developed the Endotoxin Activity Assay (EAA™) diagnostic platform. This platform helps physicians make informed treatment decisions by measuring the level of endotoxin, a toxin present in the bloodstream during sepsis. Spectral Medical Inc's dedication to research and development has led to groundbreaking advancements in the field of sepsis management, making it a prominent player in the healthcare industry.

Spectral Medical Inc has achieved several significant milestones throughout its history. Notably, the company developed and commercialized its flagship product, the Spectral Apheresis Machine (SAM), which received regulatory approval in multiple jurisdictions. It successfully completed clinical trials and obtained clearance from the U.S. FDA for the use of SAM in critically ill patients with septic shock. Moreover, Spectral Medical Inc has collaborated with leading medical centers and research institutions to further validate the efficacy of SAM. These achievements highlight the company's commitment to advancing critical care medicine and improving patient outcomes.

Spectral Medical Inc is primarily present in multiple countries and regions. The company has a significant presence in Canada, where it is headquartered, and operates in various provinces and territories across the country. Additionally, Spectral Medical Inc has expanded its operations internationally. The company is also present in the United States, focusing on key states such as California, New York, and Texas. Furthermore, Spectral Medical Inc has established its presence in European countries, including Germany, France, and the United Kingdom. With its global reach and expanding market presence, Spectral Medical Inc continues to serve customers and stakeholders in diverse countries and regions worldwide.

Spectral Medical Inc represents a set of core values and corporate philosophy that drive its mission and operations. Committed to advancing the field of critical care medicine, Spectral Medical Inc upholds principles of innovation, collaboration, and patient-centricity. The company prioritizes research and development to provide cutting-edge medical solutions for the diagnosis and treatment of life-threatening conditions. By leveraging advanced technology and expertise, Spectral Medical Inc strives to improve patient outcomes and enhance healthcare practices. As a leader in its field, the company continuously pursues excellence, integrity, and a steadfast commitment to delivering valuable solutions for critical care patients.

Analysts currently set an average price target of 3,16 CAD for the Spectral Medical stock (median: 3,16 CAD), implying +125,9 % versus the latest price. The consensus is based on 6 analyst ratings.

Spectral Medical Analyytikkojen kursstavoitteet 2026

6 analysts currently rate the Spectral Medical stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Spectral Medical to generate revenue of 2,81 M CAD and earnings per share of −0,03 CAD.

Spectral Medical Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Spectral Medical share trades at 0,87 EUR (1,40 CAD).

The Spectral Medical share (EDT.TO) is listed on 3 stock exchanges, including: Frankfurt (SD4.F), Toronto (EDT.TO).

Spectral Medical Inc. is a leading company in the field of diagnostic tests and treatment of severe diseases in intensive care medicine. The company is headquartered in Toronto, Canada and is listed on the Toronto Stock Exchange. The business model of Spectral Medical Inc. focuses on the development, production, and marketing of products and solutions that contribute to the improvement of the treatment of patients in critical conditions. The company operates two main divisions, namely the Therapeutic Division and the Diagnostic Division. Both divisions produce products that focus on the diagnosis and treatment of patients in intensive care. The Therapeutic Division of Spectral Medical Inc. produces products known as Apheresis Systems. These systems are used for the removal of toxins and excess fluids from the patient's blood. The blood is passed through the system and the unwanted substances are removed. The clean blood fluid is then returned to the patient's body. The Apheresis System has proven to be an effective treatment for patients suffering from severe diseases such as sepsis and multiorgan failure. The Diagnostic Division of Spectral Medical Inc. produces products known as endotoxin tests. Endotoxins are produced by the breakdown of bacteria and are recognized by the body as harmful substances. The endotoxin tests by Spectral Medical Inc. are used for rapid and accurate diagnosis of sepsis, a life-threatening disease caused by an infection. Spectral Medical Inc. is also committed to advancing research and development in the field of intensive care medicine. The company has close relationships with leading medical research institutions and works closely with intensivists to find innovative solutions to industry challenges. The business model of Spectral Medical Inc. is based on strategic partnerships with key players in the healthcare industry, such as hospitals, clinics, and research institutes. The company aims to provide its customers with first-class products and services and to offer them a comprehensive medical solution. In summary, Spectral Medical Inc. is a company that focuses on the development and marketing of solutions that contribute to the improvement of intensive care medicine. The company offers products that help save patients' lives by combating life-threatening diseases such as sepsis and multiorgan failure. Spectral Medical Inc. aims to find innovative solutions to the most serious problems in intensive care medicine and to support its customers with first-class products and services.

odotettu liikevaihto Spectral Medical on 2,81 M CAD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Spectral Medical on −9,22 M CAD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Spectral Medical:n hinta-voitto-suhde (P/E) on tällä hetkellä −44,30. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Spectral Medical-osakkeen arvostusta.

Spectral Medical:n hinta-myynti-suhde (P/S) on tällä hetkellä 145,48. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Spectral Medical-osakkeen arvostuskennuslukuna.

Spectral Medical:n Eulpool-laatuscore on 3/10.

Spectral Medical:n ISIN on CA8475771033. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Spectral Medical:n WKN on A12HJ9. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Spectral Medical:n ticker on EDT.TO. Tämä pörssinoteeraus käytetään Spectral Medical-osakkeiden kauppaan pörssissä.

Spectral Medical maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Spectral Medical kuuluu sektoriin 'Terveydenhuolto'.

Spectral Medical:n osingot jaetaan valuutassa CAD.